Indications
Felodipine belongs to the dihydropyridine class of calcium channel blockers (CCBs) and is approved by the United States Food and Drug Administration (FDA) for the management and treatment of essential hypertension.
FDA-Approved Indications
Apart from managing essential hypertension, felodipine is recognized for its ability to reduce blood pressure levels, thereby diminishing the risk of cardiovascular morbidity and mortality. A key advantage of felodipine's antihypertensive effect is its notable impact on decreasing the incidence of strokes. For individuals with mild-to-moderate hypertension, felodipine extended-release (ER) monotherapy demonstrates comparable efficacy to cardioselective beta blockers, thiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors, and other calcium channel antagonists. For individuals experiencing severe hypertension unresponsive to beta blockers and diuretics, felodipine ER can serve be an add-on therapy.[1][2][3] The American College of Cardiology/American Heart Association (ACC/AHA) endorses the use of felodipine in the management of hypertension.[4]
Off-Label Uses
The off-label uses of felodipine include its application in renovascular hypertension, pulmonary hypertension, chronic stable angina pectoris,[5] and congestive heart failure.[6] Felodipine's off-label applications extend to preventing the decline in renal function caused by calcineurin inhibitors in lung transplantation patients.[7] In addition, felodipine has shown potential efficacy in bleomycin-induced pulmonary fibrosis in preclinical studies. However, further research is essential before considering Felodipine for preventing bleomycin-induced pulmonary fibrosis in humans.[8]
Mechanism of Action
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
The first step in vascular smooth muscle contraction is the calcium influx into the smooth muscle cell via voltage-dependent L-type calcium channels. Cytosolic calcium binding to calmodulin follows this action, activating myosin light-chain kinase (MLCK). The activated MLCK phosphorylates the myosin light chain, resulting in the attachment of the myosin head with actin, ultimately causing smooth muscle contraction and vasoconstriction. The vascular smooth muscle contraction causes an increase in peripheral vascular resistance and blood pressure.[9]
Like the other dihydropyridine CCBs, Felodipine blocks the voltage-dependent L-type calcium channels and prevents calcium entry into the smooth muscle cell. Reduced cytosolic calcium decreases peripheral vascular resistance, resulting in vasodilation and a decrease in blood pressure. Felodipine selectively dilates arterioles and has no impact on venous vessels. In the in-vitro studies, research shows that Felodipine has a higher selectivity than other commonly used dihydropyridine CCBs like Amlodipine and Nifedipine for vascular tissue compared to cardiac tissue. Also, the clinical trials of Felodipine have not shown any negative inotropic effect.[10] Felodipine results in a dose-dependent decrease in systolic and diastolic blood pressure. Additionally, Felodipine causes a reflex increase in heart rate (reflex tachycardia).
Pharmacokinetics
Absorption: Felodipine is almost completely absorbed after oral administration. However, the bioavailability is only about 20% because of the extensive first-pass metabolism of Felodipine—the plasma concentration increases when administered with a high-fat or high-carbohydrate diet. Additionally, grapefruit juice administration increases the plasma concentration of Felodipine.[11]
Distribution: Felodipine is highly protein-bound and has a high volume of distribution (about 10 L/kg)—administration with alcohol results in a significant increase in absorption. Peak plasma concentration (Cmax) increased by almost 150%, and time to peak plasma concentration (Tmax) decreased by 1 hour after alcohol intake in simulation. Concurrent administration of alcohol with Felodipine should be avoided.[12]
Metabolism: Felodipine is metabolized in the liver and weakly inhibits CYP3A4 and CYP2D6 enzymes.[13][14]
Elimination: Approximately 70% of felodipine is excreted as metabolites in the urine; biliary secretion is a minor route of eliminating Felodipine, with 10% of the administered dose recovered in the feces.[15][16]
Administration
Available Dosage Forms and Strengths
Felodipine is an orally administered drug and is available in strengths of 2.5 mg, 5 mg, and 10 mg.
Adult Dosage
Felodipine dosing is often an ER tablet. The ER formulation offers several benefits, including daily dosing, minimal drug interactions, and fewer adverse effects. Therefore, starting the patient on a 5 mg dose of Felodipine ER daily is recommended. If the dose needs to be adjusted, a decrease or increase of 2.5 mg is recommended every 2 weeks. According to ACC/AHA, the recommended daily dosage range for felodipine is 2.5 to 10 mg.[4] The tablet should be swallowed whole and not crushed or chewed. It can be taken with or without food or with a light meal.
Specific Patient Populations
Hepatic impairment: Felodipine is not recommended in patients with hepatic impairment. Patients with liver impairment have higher plasma concentrations of felodipine since it undergoes hepatic metabolism and, if needed, is started at 2.5 mg daily. These patients need blood pressure monitoring during dose adjustment.[17][15]
Renal impairment: Felodipine is safe for use in patients with renal failure.[18]
Pregnancy considerations: In animal studies, felodipine has been shown to cause teratogenic effects, including digital anomalies and ossification of terminal phalanges. Felodipine is a former pregnancy category C drug. According to ACOG (American College of Obstetricians and Gynecologists) guidelines, if CCBs are used during pregnancy, then felodipine is preferred.[19]
Breastfeeding considerations: No clinical information is available on using felodipine during breastfeeding. It is not known whether felodipine is present in human milk. Severe adverse reactions may occur in infants; hence, an alternate drug is preferred.[20]
Pediatric patients: Felodipine is not approved by the FDA for pediatric hypertension.[21] However, according to American Academy of Pediatrics guidelines, the recommended dosage of felodipine for patients aged 6 and older is 2.5 mg.[22]
Older patients: For patients 65 and older, initiating treatment with a low dose of felodipine (2.5 mg) is advised, with strict blood pressure monitoring during dose adjustments.[23]
Adverse Effects
The adverse effects of felodipine are classified as either dose-dependent or dose-independent.
- The common dose-dependent adverse effects of felodipine include peripheral edema, flushing, palpitations, and headaches. The most common clinical side effect of Felodipine use is peripheral edema. The frequency of peripheral edema is higher in individuals taking a higher dose of felodipine and elderly individuals. The incidence of peripheral edema is about 30% in elderly patients taking 20 mg of felodipine daily. Felodipine selectively dilates the arterioles, which increases intra-capillary pressure, causing extravasation of fluid into the interstitial space and resulting in peripheral edema. ACE inhibitors or angiotensin receptor blockers can prevent peripheral edema. Flushing and headaches also occur because of the vasodilatory effects of felodipine. Palpitations may occur because of reflex tachycardia.
- In older adults with hypertension, initiating CCBs like felodipine frequently triggers a prescribing cascade, resulting in the subsequent unnecessary prescription of diuretics. Evaluating whether the edema is attributed to an underlying medical condition or is a result of Felodipine use is a risk mitigation strategy.[24]
- The dose-independent adverse effects of felodipine include fatigue, nausea, and gingival hyperplasia. Gingival hyperplasia occurs in less than 1% of patients and is more common in individuals with poor dental hygiene. The mechanism of gingival hyperplasia is overexpression of growth factors due to high concentrations of calcium ions, leading to fibroblast proliferation and chronic inflammatory cell infiltration.[25] Gingival hyperplasia is usually reversible on discontinuation of felodipine.[26]
Drug-Drug Interactions
Cytochrome P450 3A4 metabolizes felodipine.
- The plasma level of felodipine increases when used in conjunction with CYP 3A4 inhibitors such as azole antifungals (Itraconazole and Ketoconazole), macrolide antibiotics (Clarithromycin and Azithromycin), HIV protease inhibitors, immunosuppressants (Cyclosporine), Cimetidine, or grapefruit juice.[2]
- The plasma level and efficacy of felodipine decrease when co-administered with CYP3A4 inducers such as anticonvulsants (Phenytoin and Carbamazepine), St John’s wort, or rifampicin.
- When Metoprolol is subsequently administered with a conventional Felodipine formulation to treat essential hypertension, the plasma concentration of Metoprolol increases while that of felodipine remains unchanged.
- If felodipine is co-administered with Theophylline, it results in a decrease in the plasma concentration of Theophylline.[27]
- CCBs and statins are frequently prescribed in patients with cardiovascular risk factors. In a study, acute kidney injury, hyperkalemia, acute myocardial infarction, and acute ischemic stroke were increased due to interaction between CYP3A4-metabolized statins and CCBs that inhibit CYP3A4, like Felodipine.[28]
Contraindications
The absolute contraindication of Felodipine use includes hypersensitivity to felodipine or excipients. The relative contraindications for the use of felodipine include:
- Liver failure: Patients with liver failure cannot metabolize felodipine, resulting in elevated plasma concentrations.
- Severe hypotension: Dihydropyridine calcium channel antagonists should not be used in patients with severe hypotension as they may precipitate the condition and cause syncope.
- Acute coronary syndrome: Felodipine has a significant vasodilatory effect, which results in reflex tachycardia, increasing the myocardial oxygen demand and worsening myocardial ischemia.
- Pregnancy and lactation: In animal studies, felodipine has been shown to cause teratogenic effects, including digital anomalies and ossification of terminal phalanges. It is a former FDA pregnancy category C drug.[20]
Monitoring
It is essential for healthcare personnel and patients to monitor blood pressure and heart rate regularly. Routine laboratory monitoring is not necessary. Patients should undergo regular assessment for adverse effects such as peripheral edema, flushing, headache, or dizziness, and the provider should titrate the dose accordingly.[29] Cardiovascular risk assessment is a contemporary paradigm for stratifying patients with hypertension for clinical management and prevention of cardiovascular disease.[30]
Toxicity
A mild-to-moderate overdose of felodipine can result in hypotension secondary to peripheral vasodilation and reflex tachycardia. However, a severe overdose of felodipine can cause life-threatening profound hypotension and bradycardia. Case fatality due to profound, refractory circulatory collapse overdose has been reported in the literature.[31] The risk of overdose increases in elderly individuals, patients with liver impairment, and concomitant administration of felodipine with beta blockers. Overdose symptoms can include lightheadedness, syncope, altered mental status, and shock secondary to profound hypotension. The insulin release from the pancreas depends on calcium influx through the L-type channels. Felodipine blocks these calcium channels and results in hyperglycemia because of decreased insulin release.[32]
The first step in managing Felodipine overdose is maintaining a patent airway. Patients who have consumed an excess of felodipine ER tablets but have not yet developed any symptoms should be started on gastrointestinal decontamination with whole bowel irrigation if they present within 6 to 8 hours of drug ingestion. Patients with hypotension should undergo resuscitation with IV fluids. However, caution is necessary for individuals with congestive heart failure and pulmonary edema. Vasopressor therapy with dopamine or norepinephrine is an as-needed option for hypotension. IV calcium gluconate or calcium chloride (given via central line) are also options in treating Felodipine overdose.
In patients with severe overdose, atropine should be administered IV for bradycardia. The vital signs, serum electrolytes, especially potassium, blood glucose, urine output, and ECG, should be monitored regularly. Hyperinsulinemia-euglycemia therapy is also an established treatment for CCB overdose.[33] This therapy helps mobilize glucose from the peripheral tissue to serve as an alternative energy source for the myocardium.[34]
Enhancing Healthcare Team Outcomes
Felodipine ER, with daily administration, is a convenient-to-use antihypertensive medication. Healthcare personnel should be aware of the indications and adverse effects of felodipine. Clinicians need to obtain an appropriate medication history to look for drug interactions since CYP3A4 metabolizes felodipine. The healthcare personnel, including pharmacists, should educate the patients regarding medication adherence and regular blood pressure monitoring. If patients develop symptomatic hypotension, discontinue the medicine immediately and transfer to the emergency department.
Prescribers (MDs, DOs, NPs, PAs) should accurately determine the initial and maintenance dose of felodipine. The pharmacist should verify that all dosing suits the clinical scenario and report any discrepancies. The pharmacy should also perform medication reconciliation since, as discussed, felodipine can have significant drug-drug interactions. Nurses will be in charge of administration for inpatients, monitoring the patient on subsequent outpatient visits, monitoring for adverse reactions, medication compliance, and therapy effectiveness, and reporting any negative findings to the healthcare team. The outcomes of a cohort study demonstrated the significance of the pharmacist/physician team approach, which incorporated CCBs (such as felodipine) and various antihypertensive agents. This approach proved more effective than standard care in patients with treatment-resistant hypertension.[35] Felodipine therapy requires an interprofessional team approach, including clinicians, specialists, specialty-trained nurses, and pharmacists, all collaborating to achieve optimal patient results.
References
Paz MA, de-La-Sierra A, Sáez M, Barceló MA, Rodríguez JJ, Castro S, Lagarón C, Garrido JM, Vera P, Coll-de-Tuero G. Treatment efficacy of anti-hypertensive drugs in monotherapy or combination: ATOM systematic review and meta-analysis of randomized clinical trials according to PRISMA statement. Medicine. 2016 Jul:95(30):e4071. doi: 10.1097/MD.0000000000004071. Epub [PubMed PMID: 27472680]
Level 1 (high-level) evidenceTodd PA, Faulds D. Felodipine. A review of the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders. Drugs. 1992 Aug:44(2):251-77 [PubMed PMID: 1382018]
Yedinak KC, Lopez LM. Felodipine: a new dihydropyridine calcium-channel antagonist. DICP : the annals of pharmacotherapy. 1991 Nov:25(11):1193-206 [PubMed PMID: 1763537]
Level 3 (low-level) evidenceWhelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, DePalma SM, Gidding S, Jamerson KA, Jones DW, MacLaughlin EJ, Muntner P, Ovbiagele B, Smith SC Jr, Spencer CC, Stafford RS, Taler SJ, Thomas RJ, Williams KA Sr, Williamson JD, Wright JT Jr. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension (Dallas, Tex. : 1979). 2018 Jun:71(6):e13-e115. doi: 10.1161/HYP.0000000000000065. Epub 2017 Nov 13 [PubMed PMID: 29133356]
Level 1 (high-level) evidenceNavadiya K, Tiwari S. Pharmacology, Efficacy and Safety of Felodipine with a Focus on Hypertension and Angina Pectoris. Current drug safety. 2015:10(3):194-201 [PubMed PMID: 25973793]
Anand I. Stable but Progressive Nature of Heart Failure: Considerations for Primary Care Physicians. American journal of cardiovascular drugs : drugs, devices, and other interventions. 2018 Oct:18(5):333-345. doi: 10.1007/s40256-018-0277-0. Epub [PubMed PMID: 29761293]
Hornum M, Iversen M, Oturai P, Andersen MJ, Zemtsovski M, Bredahl P, Bjarnason NH, Christensen KB, Carlsen J, Møller CH, Feldt-Rasmussen B, Perch M. Felodipine and renal function in lung transplantation: A randomized placebo-controlled trial. The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation. 2020 Jun:39(6):541-550. doi: 10.1016/j.healun.2020.01.1342. Epub 2020 Feb 13 [PubMed PMID: 32061508]
Level 1 (high-level) evidenceTanaka KI, Niino T, Ishihara T, Takafuji A, Takayama T, Kanda Y, Sugizaki T, Tamura F, Kurotsu S, Kawahara M, Mizushima T. Protective and therapeutic effect of felodipine against bleomycin-induced pulmonary fibrosis in mice. Scientific reports. 2017 Jun 13:7(1):3439. doi: 10.1038/s41598-017-03676-y. Epub 2017 Jun 13 [PubMed PMID: 28611390]
Katz AM. Pharmacology and mechanisms of action of calcium-channel blockers. Journal of clinical hypertension. 1986 Sep:2(3 Suppl):28S-37S [PubMed PMID: 3540226]
Dhein S, Salameh A, Berkels R, Klaus W. Dual mode of action of dihydropyridine calcium antagonists: a role for nitric oxide. Drugs. 1999 Sep:58(3):397-404 [PubMed PMID: 10493269]
Level 3 (low-level) evidenceBailey DG, Dresser G, Arnold JM. Grapefruit-medication interactions: forbidden fruit or avoidable consequences? CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2013 Mar 5:185(4):309-16. doi: 10.1503/cmaj.120951. Epub 2012 Nov 26 [PubMed PMID: 23184849]
Fagerberg JH, Sjögren E, Bergström CAS. Concomitant intake of alcohol may increase the absorption of poorly soluble drugs. European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2015 Jan 25:67():12-20. doi: 10.1016/j.ejps.2014.10.017. Epub 2014 Oct 31 [PubMed PMID: 25444841]
Snyder BD, Rowland A, Polasek TM, Miners JO, Doogue MP. Evaluation of felodipine as a potential perpetrator of pharmacokinetic drug-drug interactions. European journal of clinical pharmacology. 2014 Sep:70(9):1115-22. doi: 10.1007/s00228-014-1716-8. Epub 2014 Jul 17 [PubMed PMID: 25028073]
. Felodipine. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643617]
Hsiao CL, Wu YC, Hsu KY. Pharmacokinetics of felodipine extended-release tablets in healthy Taiwanese subjects: a retrospective review. Arzneimittel-Forschung. 2011:61(8):444-51 [PubMed PMID: 21950148]
Level 2 (mid-level) evidenceDunselman PH, Edgar B. Felodipine clinical pharmacokinetics. Clinical pharmacokinetics. 1991 Dec:21(6):418-30 [PubMed PMID: 1782737]
Regårdh CG, Edgar B, Olsson R, Kendall M, Collste P, Shansky C. Pharmacokinetics of felodipine in patients with liver disease. European journal of clinical pharmacology. 1989:36(5):473-9 [PubMed PMID: 2753065]
Larsson R, Karlberg BE, Gelin A, Aberg J, Regårdh CG. Acute and steady-state pharmacokinetics and antihypertensive effects of felodipine in patients with normal and impaired renal function. Journal of clinical pharmacology. 1990 Nov:30(11):1020-30 [PubMed PMID: 2243149]
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 203: Chronic Hypertension in Pregnancy. Obstetrics and gynecology. 2019 Jan:133(1):e26-e50. doi: 10.1097/AOG.0000000000003020. Epub [PubMed PMID: 30575676]
. Felodipine. Drugs and Lactation Database (LactMed®). 2006:(): [PubMed PMID: 29999713]
Chu PY, Campbell MJ, Miller SG, Hill KD. Anti-hypertensive drugs in children and adolescents. World journal of cardiology. 2014 May 26:6(5):234-44. doi: 10.4330/wjc.v6.i5.234. Epub [PubMed PMID: 24944754]
Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, de Ferranti SD, Dionne JM, Falkner B, Flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM, SUBCOMMITTEE ON SCREENING AND MANAGEMENT OF HIGH BLOOD PRESSURE IN CHILDREN. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and Adolescents. Pediatrics. 2017 Sep:140(3):. pii: e20171904. doi: 10.1542/peds.2017-1904. Epub 2017 Aug 21 [PubMed PMID: 28827377]
Level 1 (high-level) evidencevan Ree JW, van der Pol GA. Low dosages of felodipine ER once daily as monotherapy in elderly hypertensive patients: effect on ambulatory blood pressure and quality of life. Journal of human hypertension. 1996 Sep:10(9):613-8 [PubMed PMID: 8953207]
Level 1 (high-level) evidenceSavage RD, Visentin JD, Bronskill SE, Wang X, Gruneir A, Giannakeas V, Guan J, Lam K, Luke MJ, Read SH, Stall NM, Wu W, Zhu L, Rochon PA, McCarthy LM. Evaluation of a Common Prescribing Cascade of Calcium Channel Blockers and Diuretics in Older Adults With Hypertension. JAMA internal medicine. 2020 May 1:180(5):643-651. doi: 10.1001/jamainternmed.2019.7087. Epub [PubMed PMID: 32091538]
Elmfeldt D, Hedner T, Westerling S. Felodipine in hypertension--a review. Journal of cardiovascular pharmacology. 1987:10 Suppl 1():S154-60 [PubMed PMID: 2442509]
Khzam N, Bailey D, Yie HS, Bakr MM. Gingival Enlargement Induced by Felodipine Resolves with a Conventional Periodontal Treatment and Drug Modification. Case reports in dentistry. 2016:2016():1095927. doi: 10.1155/2016/1095927. Epub 2016 Feb 29 [PubMed PMID: 27034854]
Level 3 (low-level) evidenceBratel T, Billing B, Dahlqvist R. Felodipine reduces the absorption of theophylline in man. European journal of clinical pharmacology. 1989:36(5):481-5 [PubMed PMID: 2753066]
Wang YC, Hsieh TC, Chou CL, Wu JL, Fang TC. Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers: A Nationwide Population-Based Study. Medicine. 2016 Jan:95(2):e2487. doi: 10.1097/MD.0000000000002487. Epub [PubMed PMID: 26765458]
. Calcium Channel Blockers. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012:(): [PubMed PMID: 31643892]
Wang MC, Lloyd-Jones DM. Cardiovascular Risk Assessment in Hypertensive Patients. American journal of hypertension. 2021 Jun 22:34(6):569-577. doi: 10.1093/ajh/hpab021. Epub [PubMed PMID: 33503227]
Lota H, Powell N, Negus R, Leonard R, Manikon M. A case of fatal felodipine overdose. Acute medicine. 2008:7(1):39-42 [PubMed PMID: 21607228]
Level 3 (low-level) evidenceProano L, Chiang WK, Wang RY. Calcium channel blocker overdose. The American journal of emergency medicine. 1995 Jul:13(4):444-50 [PubMed PMID: 7605536]
Level 3 (low-level) evidenceGreene SL, Gawarammana I, Wood DM, Jones AL, Dargan PI. Relative safety of hyperinsulinaemia/euglycaemia therapy in the management of calcium channel blocker overdose: a prospective observational study. Intensive care medicine. 2007 Nov:33(11):2019-24 [PubMed PMID: 17622512]
Level 2 (mid-level) evidenceBurkes R, Wendorf G. A multifaceted approach to calcium channel blocker overdose: a case report and literature review. Clinical case reports. 2015 Jul:3(7):566-9. doi: 10.1002/ccr3.300. Epub 2015 May 18 [PubMed PMID: 26273444]
Level 3 (low-level) evidenceSmith SM, Carris NW, Dietrich E, Gums JG, Uribe L, Coffey CS, Gums TH, Carter BL. Physician-pharmacist collaboration versus usual care for treatment-resistant hypertension. Journal of the American Society of Hypertension : JASH. 2016 Apr:10(4):307-17. doi: 10.1016/j.jash.2016.01.010. Epub 2016 Jan 18 [PubMed PMID: 26852290]